Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD1.
The recommended and maximum dose of Anoro Ellipta (UMEC/VI 55/22 mcg) is one inhalation once a day. If a dose is missed the next dose should be taken at the usual time the next day1.
In a post hoc, pooled analysis of 3 RCTs at 24 weeks in patients not on maintenance therapy (for ≥ 30 days before screening), Anoro demonstrated:
with an extra 146mL improvement in trough FEV14,5
A cross-sectional analysis of 818 COPD patients found that, despite treatment with tiotropium monotherapy, approximately 50% continue to suffer moderate to severe breathlessness (mMRC≥2)3.
Start with Anoro as an initial maintenance therapy in your symptomatic adult COPD patients.
Anoro was well tolerated and demonstrated a safety profile comparable to tiotropium HandiHaler4.
In a 8 week, open-label, crossover study in patients not on maintenance therapy (for ≥ 2 weeks prior to randomisation)6:Anoro provided a 38% reduction in rescue medication usage vs Spiolto (difference: 0.25 puffs/day)6.
with an extra 52 mL improvement in trough FEV16
COPD assessment test (CAT) pad questionnaire to measure the impact of COPD on a person’s life.Order now
Ellipta inhalation training whistle that helps patients understand the correct inspiratory flow needed to use the Ellipta device.Order now
Ellipta Demonstration device for healthcare professionals to show patients how to use the Ellipta device correctly.Order now
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2020 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
Anoro Ellipta was developed in collaboration with Innoviva.
Last updated: November 2020. PM-GB-UCV-WCNT-190010 V3.0